Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Faulds D, Goa KL, Benfield P.

Drugs. 1993 Sep;46(3):377. doi: 10.1007/BF03259110. No abstract available.

PMID:
28474316
2.

Need for revision of diagnostic limits for medullary thyroid carcinoma with a new immunochemiluminometric calcitonin assay.

Ramachandran R, Benfield P, Dhillo WS, White S, Chapman R, Meeran K, Donaldson M, Martin NM.

Clin Chem. 2009 Dec;55(12):2225-6. doi: 10.1373/clinchem.2009.129361. Epub 2009 Oct 15. No abstract available.

3.

Excitation energies in density functional theory: an evaluation and a diagnostic test.

Peach MJ, Benfield P, Helgaker T, Tozer DJ.

J Chem Phys. 2008 Jan 28;128(4):044118. doi: 10.1063/1.2831900.

PMID:
18247941
4.
5.

Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.

Markwalder JA, Arnone MR, Benfield PA, Boisclair M, Burton CR, Chang CH, Cox SS, Czerniak PM, Dean CL, Doleniak D, Grafstrom R, Harrison BA, Kaltenbach RF 3rd, Nugiel DA, Rossi KA, Sherk SR, Sisk LM, Stouten P, Trainor GL, Worland P, Seitz SP.

J Med Chem. 2004 Nov 18;47(24):5894-911.

PMID:
15537345
6.

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.

Yue EW, DiMeo SV, Higley CA, Markwalder JA, Burton CR, Benfield PA, Grafstrom RH, Cox S, Muckelbauer JK, Smallwood AM, Chen H, Chang CH, Trainor GL, Seitz SP.

Bioorg Med Chem Lett. 2004 Jan 19;14(2):343-6.

PMID:
14698155
7.

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2).

Yue EW, Higley CA, DiMeo SV, Carini DJ, Nugiel DA, Benware C, Benfield PA, Burton CR, Cox S, Grafstrom RH, Sharp DM, Sisk LM, Boylan JF, Muckelbauer JK, Smallwood AM, Chen H, Chang CH, Seitz SP, Trainor GL.

J Med Chem. 2002 Nov 21;45(24):5233-48.

PMID:
12431051
8.

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern.

Nugiel DA, Vidwans A, Etzkorn AM, Rossi KA, Benfield PA, Burton CR, Cox S, Doleniak D, Seitz SP.

J Med Chem. 2002 Nov 21;45(24):5224-32.

PMID:
12431050
9.

Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.

Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P, Rolfe M, Caligiuri M, Benfield PA, Auger KR, Copeland RA.

Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14734-9. Epub 2002 Oct 29.

10.

Identification of selective inhibitors of cyclin dependent kinase 4.

Carini DJ, Kaltenbach RF, Liu J, Benfield PA, Boylan J, Boisclair M, Brizuela L, Burton CR, Cox S, Grafstrom R, Harrison BA, Harrison K, Akamike E, Markwalder JA, Nakano Y, Seitz SP, Sharp DM, Trainor GL, Sielecki TM.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2209-11.

PMID:
11514172
11.

Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization.

Lai Z, Ferry KV, Diamond MA, Wee KE, Kim YB, Ma J, Yang T, Benfield PA, Copeland RA, Auger KR.

J Biol Chem. 2001 Aug 17;276(33):31357-67. Epub 2001 Jun 7.

12.

Quinazolines as cyclin dependent kinase inhibitors.

Sielecki TM, Johnson TL, Liu J, Muckelbauer JK, Grafstrom RH, Cox S, Boylan J, Burton CR, Chen H, Smallwood A, Chang CH, Boisclair M, Benfield PA, Trainor GL, Seitz SP.

Bioorg Med Chem Lett. 2001 May 7;11(9):1157-60.

PMID:
11354366
13.

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.

Nugiel DA, Etzkorn AM, Vidwans A, Benfield PA, Boisclair M, Burton CR, Cox S, Czerniak PM, Doleniak D, Seitz SP.

J Med Chem. 2001 Apr 26;44(9):1334-6. No abstract available.

PMID:
11311054
14.

SCF(beta-TRCP) and phosphorylation dependent ubiquitinationof I kappa B alpha catalyzed by Ubc3 and Ubc4.

Strack P, Caligiuri M, Pelletier M, Boisclair M, Theodoras A, Beer-Romero P, Glass S, Parsons T, Copeland RA, Auger KR, Benfield P, Brizuela L, Rolfe M.

Oncogene. 2000 Jul 20;19(31):3529-36.

15.

Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.

Sielecki TM, Boylan JF, Benfield PA, Trainor GL.

J Med Chem. 2000 Jan 13;43(1):1-18. Review. No abstract available.

PMID:
10633033
16.

Fosphenytoin. Pharmacoeconomic implications of therapy.

Holliday SM, Benfield P, Plosker GL.

Pharmacoeconomics. 1998 Dec;14(6):685-90. Review.

PMID:
10346419
17.

Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1.

Bogdan JA, Adams-Burton C, Pedicord DL, Sukovich DA, Benfield PA, Corjay MH, Stoltenborg JK, Dicker IB.

Biochem J. 1998 Dec 1;336 ( Pt 2):471-81.

18.

Orlistat.

McNeely W, Benfield P.

Drugs. 1998 Aug;56(2):241-9; discussion 250. Review.

PMID:
9711448
19.

Tazarotene.

Foster RH, Brogden RN, Benfield P.

Drugs. 1998 May;55(5):705-11; discussion 712. Review.

PMID:
9585866
20.

Fluoxetine. A pharmacoeconomic review of its use in depression.

Wilde MI, Benfield P.

Pharmacoeconomics. 1998 May;13(5 Pt 1):543-61. Review.

PMID:
10180753
21.

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

Markham A, Benfield P.

CNS Drugs. 1998 Apr;9(4):280. doi: 10.1007/BF03257356. No abstract available.

PMID:
27521011
22.
23.
24.

Meropenem. A pharmacoeconomic review of its use in serious infections.

Holliday SM, Benfield P.

Pharmacoeconomics. 1998 Mar;13(3):359-77. Erratum in: Pharmacoeconomics 1998 May;13(5):518.

PMID:
10178661
25.

Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.

Plosker GL, Foster RH, Benfield P.

Pharmacoeconomics. 1998 Jan;13(1 Pt 1):91-106. Review.

PMID:
10175990
26.

Nelfinavir.

Perry CM, Benfield P.

Drugs. 1997 Jul;54(1):81-7; discussion 88. Review.

PMID:
9211082
27.
28.

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Markham A, Benfield P.

CNS Drugs. 1997 Apr;7(4):328-40. doi: 10.2165/00023210-199707040-00005. Erratum in: CNS Drugs. 1998 Apr;9(4):280.

PMID:
27520755
29.

Donepezil.

Bryson HM, Benfield P.

Drugs Aging. 1997 Mar;10(3):234-9; discussion 240-1. Review.

PMID:
9108896
30.

[Not Available].

Balfour JA, Benfield P.

BioDrugs. 1997 Feb;7(2):158-63.

PMID:
18031088
31.
32.

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Fulton B, Benfield P.

Drugs. 1996 Dec;52(6):869. doi: 10.1007/BF03259133. No abstract available.

PMID:
28597367
33.
34.

Moclobemide. An update of its pharmacological properties and therapeutic use.

Fulton B, Benfield P.

Drugs. 1996 Sep;52(3):450-74. Review. Erratum in: Drugs 1996 Dec;52(6):869.

PMID:
8875133
36.

Galanthamine.

Fulton B, Benfield P.

Drugs Aging. 1996 Jul;9(1):60-5; discussion 66-7. Review.

PMID:
8818586
37.

Gene expression of acyl-coenzyme-A:cholesterol-acyltransferase is upregulated in human monocytes during differentiation and foam cell formation.

Wang H, Germain SJ, Benfield PP, Gillies PJ.

Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):809-14.

PMID:
8640409
38.
39.
40.

Construction of linker-scanning mutations using PCR.

Harlow PP, Hobson GM, Benfield PA.

Methods Mol Biol. 1996;57:287-95. Review. No abstract available.

PMID:
8850015
41.

Construction of linker-scanning mutations by oligonucleotide ligation.

Hobson GM, Harlow PP, Benfield PA.

Methods Mol Biol. 1996;57:279-85. Review. No abstract available.

PMID:
8850014
42.
43.
44.
45.

Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

Holliday SM, Benfield P.

Drugs. 1995 Feb;49(2):280-94. Review.

PMID:
7729333
47.
48.

Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Peters DH, Benfield P.

Pharmacoeconomics. 1994 Oct;6(4):370-400. Review. Erratum in: Pharmacoeconomics 1995 Jun;7(6):554.

PMID:
10147474

Supplemental Content

Loading ...
Support Center